WATERTOWN, Mass.--(BUSINESS WIRE)--Acusphere, Inc. (NASDAQ:ACUS) today announced today that Olinda Carneiro, Ph.D., Scientist in Acusphere's Research Group, is scheduled to present a poster entitled "Preparation of Powder Formulations of Oxcarbezepine for Potential Use in Oral Dosage Forms" at the 2007 American Association of Pharmaceutical Scientists (AAPS) Annual Meeting and Exposition in San Diego. Dr. Carneiro’s poster focuses on oral dosage formulations of oxcarbazepine developed by Acusphere using its proprietary technology. Oxcarbazepine is the active ingredient in Trileptal®, marketed by Novartis. The drug has been approved for treatment of epilepsy. The oral dosage formulation of oxcarbazepine developed by Acusphere had a smaller and more uniform particle size distribution and enhanced dissolution rate compared to formulations made with traditional pharmaceutical methods. The poster presentation, at the San Diego Convention Center, will take place on Monday, November 12, 2007, beginning at 1:00 PM local time.
